The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The GCC dental implants market is expected to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Dental implants are artificial tooth roots that help in supporting false teeth and tooth bridges. The implant frames are made of biocompatible metals, like zirconia and titanium. They can be placed in the jawbone beneath the gum through a surgical procedure for supporting artificial teeth. This process helps in securing dentures and bridges while providing a more natural feel than conventional dentures. There are currently three types of dental implants available in the market: endosteal, subperiosteal and transosteal. Endosteal dental implants are grafted into tissues while the subperiosteal implants are attached under the gum tissue with a protruding metal frame. Transosteal implants are passed through the jawbone and gum tissue.
The GCC dental implant market is primarily driven by the rising cases of oral health problems, such as tooth decay, periodontal diseases and dental caries. This can be attributed to the high consumption of junk food, low quality of drinking water and smoking tobacco. Besides this, the increasing expenditure on dentalcare and the rising awareness about dental implant treatment and diagnosis have encouraged individuals to opt for implant procedures, like immediate implant loading and definitive restoration. Other factors, such as improper oral hygiene, the rising geriatric population, increasing demand for cosmetic dentistry and growing dental tourism, are catalyzing the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the GCC dental implants market, along with forecasts at the regional and country level from 2021-2026. Our report has categorized the market based on material, product and end use.
Breakup by Material:
Breakup by Product:
Breakup by End Use:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2020|
|Segment Coverage||Material, Product, End Use, Country|
|Countries Covered||Saudi Arabia, UAE, Qatar, Oman, Kuwait, Bahrain|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License $ 2499
Five User License $ 2999
Corporate License $ 3999
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at